Role of lifestyle and glucagon‐like peptide‐1 receptor agonists for weight loss in obesity, type 2 diabetes and steatotic liver diseases

• DOI: 10.1111/apt.17848
• Publication Date: 2024-05-30T11:57:01Z
• Authors: Anna Giannakogeorgou; Michael Roden
• Keywords: 0301 basic medicine; Liraglutide; Glucagon-Like Peptide-1 Receptor; Fatty Liver; 03 medical and health sciences; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor Agonists; Weight Loss; Humans; Hypoglycemic Agents; Obesity; Anti-Obesity Agents; Life Style

Summary Background The current obesity pandemic has given rise to associated comorbidities and complications, including type 2 diabetes metabolic dysfunction‐associated steatotic liver disease (MASLD). During the last decade, certain glucagon‐like peptide 1 receptor agonists (GLP‐1RA), originally developed as antihyperglycemic drugs, also demonstrated efficacy for weight loss. Aims To review shared pathophysiologic features of common diseases compare therapeutic strategies reduce body related complications. Methods We performed an extensive literature research describe effects lifestyle modification, first‐generation anti‐obesity GLP‐1RA on loss in humans with obesity, MASLD. Results Until recently, treatment been limited which offer moderate degree sustainability few approved drugs are either short term use or forms obesity. Some significantly decrease caloric intake weight. Liraglutide semaglutide have therefore treating people They lead a reduction hepatic fat content inflammation biopsy‐confirmed Possible limitations comprise adverse effects, adherence persistence. Conclusion Certain superior modification inducing markedly changed portfolio additional beneficial disease.